VRDN-008 Phase 1 Hits 74% IgG Reduction, Every-8-Week Dosing Possible
VRDN has more than doubled off its 52-week low of $13.18 on elevated volume (2.2× avg).
Summary
Viridian's VRDN-008 posted positive Phase 1 data in healthy volunteers: a 15-18 day half-life (up to 6x longer than first-generation Fc fragments) and 74% peak IgG reduction sustained through 8 weeks, supporting every-8-week subcutaneous dosing. No serious adverse events or dose-limiting toxicities were reported, and the drug spared albumin and LDL. Management says it will push VRDN-008 into registrational development starting with myasthenia gravis in mid-2027, pending regulatory feedback, with a two-arm Q4W/Q8W versus placebo design using the Enable enFuse on-body injector. This is the pipeline story that matters beyond Lumvoa, which just delivered its first $24.7 million commercial quarter and left $955.2 million in cash. A best-in-class Q8W FcRn profile would be a major competitive differentiator in autoantibody-mediated disease, though the value hinges on pivotal data that won't start until 2027. A conference call is scheduled for 8:00 a.m. ET today.
At the time of this announcement, VRDN was trading at $30.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.2B. The 52-week trading range was $13.18 to $34.29. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.